IN-VITRO-RESISTENZTESTUNG VON TUMOREN GEGENUEBER ZYTOSTATIKA. I: TIEREXPERIMENTELLE VORUNTERSUCHUNGEN = TEST IN VITRO DE RESISTANCE DES TUMEURS AUX CYTOSTATIQUES. I. RESULTATS D'ETUDE EXPERIMENTALE CHEZ L'ANIMALPOSSINGER K; HARTENSTEIN R; EHRHART H et al.1980; ONKOLOGIE; ISSN 0378-584X; CHE; DA. 1980; VOL. 3; NO 6; PP. 291-295; ABS. ENG; BIBL. 50 REF.Article

HYPERCOAGULABILITY IN ACUTE ESOPHAGEAL VARICEAL BLEEDINGHILLER E; HEGEMANN F; POSSINGER K et al.1981; THROMB. RES.; ISSN 0049-3848; USA; DA. 1981; VOL. 22; NO 3; PP. 243-251; BIBL. 23 REF.Article

IN-VITRO-RESISTENZTESTUNG VON TUMOREN GEGENUEBER ZYTOSTATIKA. II: UNTERSUCHUNGEN AN MENSCHLICHEN MALIGNOMEN = TEST IN VITRO DE RESISTANCE DES TUMEURS AUX CYTOSTATIQUES. II. ETUDE SUR DES TUMEURS MALIGNES CHEZ L'HOMMEPOSSINGER K; HARTENSTEIN R; EHRHART H et al.1980; ONKOLOGIE; ISSN 0378-584X; CHE; DA. 1980; VOL. 3; NO 6; PP. 297-300; ABS. ENG; BIBL. 14 REF.Article

RESISTENZTESTUNG VON MENSCHLICHEN TUMOREN GEGENUEBER CYTOSTATIKA = MESURE DE LA RESISTANCE DES TUMEURS HUMAINES AUX CYTOSTATIQUESPOSSINGER K; HARTENSTEIN R; EHRHART H et al.1976; KLIN. WSCHR.; DTSCH.; DA. 1976; VOL. 54; NO 8; PP. 349-355; ABS. ANGL.; BIBL. 35 REF.Article

RESISTENZTESTUNG MALIGNER TUMOREN. MOEGLICHKEIT ZUR ANALYSE KLINISCHER SEKUNDAER-RESISTENZENTWICKLUNG GEGENUEBER ZYTOSTATIKA. = TEST DE RESISTANCE DES TUMEURS MALIGNES. POSSIBILITES DE L'ANALYSE DU DEVELOPPEMENT D'UNE RESISTANCE SECONDAIRE CLINIQUE AUX CYTOSTATIQUESPOSSINGER K; HARTENSTEIN R; EHRHART H et al.1978; MUNCH. MED. WOCHR.; DTSCH.; DA. 1978; VOL. 120; NO 21; PP. 725-728; ABS. ANGL.; BIBL. 17 REF.Article

EINFLUSS VON HYDROXYUREA AUF DIE DNA-SYNTHESE MENSCHLICHEN KNOCHENMARKS IN VIVO = INFLUENCE DE L'HYDROXYUREE SUR LA SYNTHESE DE L'ADN DANS LA MOELLE OSSEUSE CHEZ L'HOMME (IN VIVO)HARTENSTEIN R; ERTL E; POSSINGER K et al.1979; KLIN. WSCHR.; DEU; DA. 1979; VOL. 57; NO 21; PP. 1191-1193; ABS. ENG; BIBL. 15 REF.Article

VENO-OCCLUSIVE DISEASE OF THE LIVER IN PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPYWEITZ H; GOKEL JM; LOESCHKE K et al.1982; VIRCHOWS ARCH., A; ISSN 0340-1227; DEU; DA. 1982; VOL. 395; NO 3; PP. 245-256; BIBL. 1 P.Article

Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47DDANNECKER, C; POSSINGER, K; CLASSEN, S et al.Annals of oncology. 1996, Vol 7, Num 4, pp 391-396, issn 0923-7534, 5 p.Article

Molecular genetic characteristics of lung cancer : useful as 'real' tumor markers ?FLEISCHHACKER, M; BEINERT, T; POSSINGER, K et al.Lung cancer. 1999, Vol 25, Num 1, pp 7-24, issn 0169-5002Article

c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapyLÜFTNER, D; SCHNABEL, S; POSSINGER, K et al.The International journal of biological markers. 1999, Vol 14, Num 2, pp 55-59, issn 0393-6155Article

New therapeutic approaches in primary systemic AL amyloidosisSEZER, O; EUCKER, J; SCHMID, P et al.Annals of hematology (Print). 2000, Vol 79, Num 1, pp 1-6, issn 0939-5555Article

MucormycosesEUCKER, J; SEZER, O; GRAF, Barbara et al.Mycoses. 2001, Vol 44, Num 7-8, pp 253-260, issn 0933-7407Article

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing modelLUX, Michael Patrick; HARTMANN, M; JACKISCH, C et al.Breast cancer research and treatment. 2009, Vol 117, Num 2, pp 305-317, issn 0167-6806, 13 p.Article

First Safety and Response Results of a Randomized Phase III Study with Liposomal Platin in the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)JEHN, C. F; BOULIKAS, T; KOURVETARIS, A et al.Anticancer research. 2008, Vol 28, Num 6B, pp 3961-3964, issn 0250-7005, 4 p.Article

Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer : First results of a phase III studyJEHN, C. F; BOULIKAS, T; KOURVETARIS, A et al.Anticancer research. 2007, Vol 27, Num 1A, pp 471-475, issn 0250-7005, 5 p.Article

The amino-terminal propeptide (PINP) of type i collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancerPOLLMANN, D; SIEPMANN, S; GEPPERT, R et al.Anticancer research. 2007, Vol 27, Num 4A, pp 1853-1862, issn 0250-7005, 10 p.Conference Paper

PINP as serum marker of metastatic spread to the bone in breast cancer patientsLÜFTNER, D; JOZEREAU, D; SCHILDHAUER, S et al.Anticancer research. 2005, Vol 25, Num 3A, pp 1491-1499, issn 0250-7005, 9 p.Article

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trialZANDER, A. R; KRÖGER, N; THIEL, E et al.Journal of clinical oncology. 2004, Vol 22, Num 12, pp 2273-2283, issn 0732-183X, 11 p.Article

Resolution of psoriatic skin lesions after chemotherapy with gemcitabine and vinorelbineGENVRESSE, I; FLATH, B; AKRIVAKIS, K et al.British journal of dermatology (1951). 2000, Vol 143, Num 6, pp 1326-1327, issn 0007-0963Article

Open, randomized, multicenter trial of Raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancerCOCCONI, G; CUNNINGHAM, D; VAN CUTSEM, E et al.Journal of clinical oncology. 1998, Vol 16, Num 9, pp 2943-2952, issn 0732-183XArticle

ADVIA Centaur® HER-2/neu shows value in monitoring patients with metastatic breast cancerLÜFTNER, D; CHELI, C; MICKELSON, K et al.The International journal of biological markers. 2004, Vol 19, Num 3, pp 175-182, issn 0393-6155, 8 p.Article

An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patientsREGIERER, A. C; WOLTERS, R; UFEN, M. -P et al.Annals of oncology. 2014, Vol 25, Num 3, pp 633-638, issn 0923-7534, 6 p.Article

Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancerLÜFTNER, D; RICHTER, A; GEPPERT, R et al.Anticancer research. 2003, Vol 23, Num 2A, pp 1017-1026, issn 0250-7005, 10 p.Conference Paper

Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapyCLASSEN, S; KOPP, R; POSSINGER, K et al.Tumor biology. 2002, Vol 23, Num 2, pp 70-75, issn 1010-4283Article

Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cellsELSTNER, E; WILLIAMSON, E. A; ZANG, C et al.Breast cancer research and treatment. 2002, Vol 74, Num 2, pp 155-165, issn 0167-6806Article